serval:BIB_FB3741642DC8
Systems biology applications to study mechanisms of human immunodeficiency virus latency and reactivation
10.5495/wjcid.v6.i2.6
http://www.wjgnet.com/2220-3176/full/v6/i2/6.htm
White
Cory H
author
Moesker
Bastiaan
author
Ciuffi
Angela
author
Beliakova-Bethell
Nadejda
author
article
review
2016-05-25
World Journal of Clinical Infectious Diseases
2220-3176
journal
6
2
6-21
Eradication of human immunodeficiency virus (HIV) in infected individuals is currently not possible because of the presence of the persistent cellular reservoir of latent infection. The identification of HIV latency biomarkers and a better understanding of the molecular mechanisms contributing to regulation of HIV expression might provide essential tools to eliminate these latently infected cells. This review aims at summarizing gene expression profiling and systems biology applications to studies of HIV latency and eradication. Studies comparing gene expression in latently infected and uninfected cells identify candidate latency biomarkers and novel mechanisms of latency control. Studies that profiled gene expression changes induced by existing latency reversing agents (LRAs) highlight uniting themes driving HIV reactivation and novel mechanisms that contribute to regulation of HIV expression by different LRAs. Among the reviewed gene expression studies, the common approaches included identification of differentially expressed genes and gene functional category assessment. Integration of transcriptomic data with other biological data types is presently scarce, and the field would benefit from increased adoption of these methods in future studies. In addition, designing prospective studies that use the same methods of data acquisition and statistical analyses will facilitate a more reliable identification of latency biomarkers using different model systems and the comparison of the effects of different LRAs on host factors with a role in HIV reactivation. The results from such studies would have the potential to significantly impact the process by which candidate drugs are selected and combined for future evaluations and advancement to clinical trials.
Gene expression
Microarrays
RNA-Seq
Systems biology
Human immunodeficiency virus
Viral latency
Disease eradication
Biomarkers
Molecular mechanisms
Latency reversing agents
eng
60_published
true
peer-reviewed
University of Lausanne
mailto:serval_help@unil.ch
http://www.unil.ch/serval
http://serval.unil.ch/disclaimer
https://serval.unil.ch/notice/serval:BIB_FB3741642DC8